After finishing at $18.63 in the prior trading day, Enliven Therapeutics Inc (NASDAQ: ELVN) closed at $17.59, down -5.58%. In other words, the price has decreased by -$1.04 from its previous closing price. On the day, 196384 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
Our goal is to gain a better understanding of ELVN by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.28 and its Current Ratio is at 10.28. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Jefferies on March 29, 2023, initiated with a Buy rating and assigned the stock a target price of $27.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 25 ’24 when Kintz Samuel sold 12,000 shares for $17.56 per share. The transaction valued at 210,661 led to the insider holds 0 shares of the business.
Ballal Rahul D. sold 13,278 shares of ELVN for $254,462 on Mar 20 ’24. The Director now owns 22,341 shares after completing the transaction at $19.16 per share. On Mar 19 ’24, another insider, Heyman Richard A., who serves as the Director of the company, sold 1,270 shares for $14.50 each. As a result, the insider received 18,419 and left with 143,470 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ELVN now has a Market Capitalization of 726.89M and an Enterprise Value of 474.08M.
Stock Price History:
Over the past 52 weeks, ELVN has reached a high of $24.22, while it has fallen to a 52-week low of $9.80. The 50-Day Moving Average of the stock is 15.72, while the 200-Day Moving Average is calculated to be 15.19.
Shares Statistics:
The stock has traded on average 137.52K shares per day over the past 3-months and 238.39k shares per day over the last 10 days, according to various share statistics. A total of 41.29M shares are outstanding, with a floating share count of 21.29M. Insiders hold about 48.51% of the company’s shares, while institutions hold 51.46% stake in the company. Shares short for ELVN as of Mar 15, 2024 were 4.33M with a Short Ratio of 31.48, compared to 4.91M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 10.47% and a Short% of Float of 18.57%.
Earnings Estimates
Its stock is currently analyzed by 2 different market analysts. On average, analysts expect EPS of -$0.56 for the current quarter, with a high estimate of -$0.55 and a low estimate of -$0.57, while EPS last year was -$0.8. The consensus estimate for the next quarter is -$0.63, with high estimates of -$0.6 and low estimates of -$0.65.
Analysts are recommending an EPS of between -$2.14 and -$2.63 for the fiscal current year, implying an average EPS of -$2.42. EPS for the following year is -$3.02, with 3 analysts recommending between -$2.4 and -$3.83.
